Comparison of Customized Allogenic Versus Autogenous Bone Block Graft for Alveolar Ridge Augmentation (IndiALLO)

  • STATUS
    Recruiting
  • End date
    Aug 1, 2032
  • participants needed
    26
  • sponsor
    Medical University of Graz
Send
Updated on 19 February 2026
See if I qualify

Summary

The aim of this study is to determine whether jawbone augmentations using allogeneic and autogenous bone blocks lead to comparable three-dimensional clinical and radiological outcomes.

In addition, the study seeks to investigate whether there are differences regarding safety, biocompatibility, complications, and PROMs.

Furthermore, it aims to clarify whether differences exist between the two groups with respect to implant condition (one year after implantation and during annual follow-ups for up to five years).

Details
Condition Alveolar Bone Loss
Age 18years or above
Clinical Study IdentifierNCT07419269
SponsorMedical University of Graz
Last Modified on19 February 2026

Eligibility

 Yes No Not Sure

Inclusion Criteria

-4 missing teeth that need to be replaced with dental implants
Bone ridge width insufficient for dental implant placement; <5 mm of width as measured in a cone beam computed tomography at the ideal prosthetic position
Medically healthy with no known allergies to antibiotics
Non-smoker or light smoker (< 10) or previous smoker who had quit for 5 years or more
Periodontal health, as confirmed by clinical examination (Full mouth bleeding score and full mouth plaque score < 25%) and at least one neighboring natural tooth to the defect site(s)
Age of 18 or above

Exclusion Criteria

All contraindications against implant treatment or augmentative procedures (e.g., advanced systemic diseases, corticosteroid medication, immunodeficiency, pregnancy, intention to become pregnant, breastfeeding, lack of safe contraception)
Treatments or diseases that may have an effect on bone turnover or the bone itself or non-mineralized tissue metabolism (e.g., bisphosphonates or local radiotherapy, skeletal immaturity)
Pathological fractures such as those observed in (but not limited to) Paget's disease or in metastatic bone diseases
Any active malignancy or patient undergoing treatment for a malignancy Study protocol: IndiALLO Version 4/19.03.2025 Page 9 von 32
Contraindications to the class of drugs under study, e.g., known hypersensitivity or allergy to class of drugs or the investigational product
Persistent compartment syndrome or neurovascular residua of compartment syndrome
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.